Switch to fixeddose doravirine 100 mg with islatravir 075 mg once daily in virologically suppressed adults with HIV1 on bictegravir emtricitabine and tenofovir alafenamide 48week results of a phase 3 randomised controlled doubleblind noninferiority t

Simple item page
dc.article.end-page379en
dc.article.start-page369en
dc.citation.doi10.1016/S2352-3018(24)00031-6en
dc.contributor.authorJ Molinaen
dc.contributor.authorGiuliano Rizzardinien
dc.contributor.authorC Orrellen
dc.contributor.authorA Afanien
dc.contributor.authorA Calmyen
dc.contributor.authorE et alen
dc.date.accessioned2025-03-14T06:16:14Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/44299
dc.journal.titleSwitch to fixeddose doravirine 100 mg with islatravir 075 mg once daily in virologically suppressed adults with HIV1 on bictegravir emtricitabine and tenofovir alafenamide 48week results of a phase 3 randomised controlled doubleblind noninferiority ten
dc.journal.volume11en
dc.titleSwitch to fixeddose doravirine 100 mg with islatravir 075 mg once daily in virologically suppressed adults with HIV1 on bictegravir emtricitabine and tenofovir alafenamide 48week results of a phase 3 randomised controlled doubleblind noninferiority ten
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
341.78 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)